AspyreRx
Commercial- Indications
- Type 2 diabetes
Company intelligence / Profile preview
Better Therapeutics
San Francisco, California, United Statestrust.bettertx.com ↗
- Ownership
- Private
- Employees
- ~54
- Development stage
- Commercial
01
Overview
Better Therapeutics’ lead product AspyreRx™ (formerly BT‑001), a prescription digital therapeutic delivering nCBT for adults with type 2 diabetes, received FDA authorization in July 2023. In a pivotal randomized controlled trial of over 660 patients with advanced T2D, AspyreRx achieved statistically significant and durable reductions in HbA1c at both primary and secondary endpoints. At day 180, half of subjects achieved a mean A1c reduction of up to 1.3%. Additional benefits included improved fasting glucose, reduced blood pressure and weight, improved mood/quality of life scores, lower medication use and fewer diabetes-related risks compared to control.
- Therapeutic areas
- GastroenterologyEndocrinologyCardiovascularNephrology
- Modalities
- Non-pharmacological therapyDevice (Prescription Digital Therapeutic)
- Industry
- Digital Health Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Catalyst Health Network—real-world evidence study partnerColorado Prevention Center—study partner
Beyond the preview
Go deeper on Better Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Better Therapeutics.